) --




) hit a new 52-week high Monday as it is currently trading at $106.28, above its previous 52-week high of $105.53 with 165,459 shares traded as of 9:35 a.m. ET. Average volume has been 429,700 shares over the past 30 days.

Shire has a market cap of $18.71 billion and is part of the

health care

sector and


industry. Shares are up 1% year to date as of the close of trading on Friday.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in two segments, Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 20.5, below the average drugs industry P/E ratio of 24.4 and above the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Shire as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full

Shire Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center